Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
Public ClinicalTrials.gov record NCT03916081. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% and ARQ-151 Cream 0.15% Administered QD (Quaque Die) in Adolescent and Adult Subjects With Atopic Dermatitis
Study identification
- NCT ID
- NCT03916081
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Arcutis Biotherapeutics, Inc.
- Industry
- Enrollment
- 136 participants
Conditions and interventions
Conditions
Interventions
- Roflumilast Cream 0.05% Drug
- Roflumilast Cream 0.15% Drug
- Vehicle Cream Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 30, 2019
- Primary completion
- Nov 3, 2019
- Completion
- Nov 3, 2019
- Last update posted
- Feb 12, 2023
2019
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arcutis Clinical Site 25 | Scottsdale | Arizona | 85254 | — |
| Arcutis Clinical Site 01 | San Diego | California | 92123 | — |
| Arcutis Clinical Site 19 | Hialeah | Florida | 33016 | — |
| Arcutis Clinical Site 18 | Miami | Florida | 33174 | — |
| Arcutis Clinical Site 17 | Sanford | Florida | 32771 | — |
| Arcutis Clinical Site 16 | Boise | Idaho | 83713 | — |
| Arcutis Clinical Site 12 | Indianapolis | Indiana | 46250 | — |
| Arcutis Clinical Site 13 | Plainfield | Indiana | 46168 | — |
| Arcutis Clinical Site 15 | Metairie | Louisiana | 70006 | — |
| Arcutis Clinical Site 03 | Fridley | Minnesota | 55432 | — |
| Arcutis Clinical Site 02 | High Point | North Carolina | 27262 | — |
| Arcutis Clinical Site 08 | Bexley | Ohio | 43209 | — |
| Arcutis Clinical Site 23 | Pittsburgh | Pennsylvania | 15213 | — |
| Arcutis Clinical Site 20 | Murfreesboro | Tennessee | 37130 | — |
| Arcutis Clinical Site 09 | College Station | Texas | 77845 | — |
| Arcutis Clinical Site 04 | San Antonio | Texas | 78213 | — |
| Arcutis Clinical Site 21 | Richmond | Virginia | 23224 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03916081, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 12, 2023 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03916081 live on ClinicalTrials.gov.